Clinical Trials Browser

Phase 1/2 × ensartinib × 90 days × Clear all

NCT01625234 2026-04-30

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Phase 1/2 Completed

131 enrolled 22 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT07354061 2026-04-01

TD-ENSEMBLE

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung